Search by Categories
- Insights
- Rare Disease
- Oncology
- Cell and Gene Therapy
- Medical Devices
- Consulting
- News & Analysis
-
Therapeutic Areas
Our expertise in the industry
Baxter Introduced New Injectable Pharmaceuticals to US Market; Bayer and Hologic Collaborated to Deliver Contrast-Enhanced Mammography; Labcorp Received FDA Emergency Use Authorization for Mpox PCR Test Home Collection Kit; Onkos Surgical Won FDA De Novo Nod For Antibacterial-Coated Orthopedic Implants; Heartbeam Presented Positive Results On Its Artificial Intelligence Capabilities For Detecting Arrhythmias; Cognito Therapeutics Showed Positive Non-Invasive Neuromod Results
Baxter Introduced New Injectable Pharmaceuticals to US Market On April 11, 2024, the pharmaceutical portfolio of multinational medical goods corporation Baxter International Inc. was augmented with the introduction of five new injectable medications in the US market. The goods were made to fulfill essential demands in therapeutic domains like anti-hypertensive and anti-infective drugs. Among the new products is a ready-to-use injection of norepinephrine bitartrate in 5% Dextrose, which is now available in three strengths—including a brand-new 16 mg/250 mL option—for severe, acute hypotension. This is the first and only ready-to-use…
From Lab to Market: Understanding the Evolutionary Journey and Market Landscape of Biochips
Biochips have emerged as indispensable tools in the healthcare sector, revolutionizing the way diseases are diagnosed, monitored, and treated. These miniature laboratories on a chip offer unparalleled efficiency, sensitivity, and speed in analyzing biological samples, making them invaluable in various medical applications. Their ability to simultaneously process multiple biomolecular interactions with high throughput has significantly enhanced diagnostic accuracy and therapeutic effectiveness, thereby improving patient outcomes and reducing healthcare costs. The growing benefits and importance of Biochips are evident in their ability to facilitate rapid and accurate disease diagnosis, personalized medicine,…
Roche’s Columvi Phase III STARGLO Trial; Novartis’ Fabhalta Latest Data; Vertex’s Alpine Immune Sciences Acquisition; Telix Pharmaceuticals’ TLX101-CDx Fast Track Designation; NovelMed’s NM5072 Orphan Drug Designation
Roche's Columvi Achieves Primary Endpoint of Prolonged Overall Survival in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Phase III STARGLO Trial Roche reported that the Phase III STARGLO trial successfully achieved its main goal of improving overall survival. The research revealed that individuals with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), who had previously undergone at least one treatment and were not eligible for autologous stem cell transplant, had longer life expectancy when treated with Columvi® (glofitamab) alongside gemcitabine and oxaliplatin (GemOx) compared to those treated…